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Letter
Dear Editor,
From November 2019 to date, almost six thousand papers have been published on COVID-
19, the disease caused by SARS-CoV-2 infection. As physicians working in a multidisciplinary 
centre for the cure of Hereditary Haemorrhagic Telangiectasia (HHT) in a country (Italy) that has 
been severely affected by COVID-19, we are surprised that, among this impressive amount of 
publications, there is none on HHT. Indeed, we performed our last PubMed search on 22 April 
2020, using the keywords “Hereditary Haemorrhagic Telangiectasia” OR “Hereditary 
Hemorrhagic Telangiectasia” OR “HHT” OR “Rendu-Osler-Weber” AND “COVID-19” OR 
“coronavirus”, and found no papers. This is surprising, because, although HHT is a rare disease, 
there are many reasons why we believe that it deserves special attention during the COVID-19 
pandemic. One reason is that almost 95% of subjects with HHT has spontaneous and sudden 
epistaxis, which sometimes may simply require self-treatment and home remedies, but may also 
lead to procedural interventions in medical offices, emergency departments, hospitals, and 
operating rooms [1]. The manipulation of nostrils, nasal cavity, or nasopharynx, either done at 
home by family members or caregivers or performed in a hospital setting by medical personnel, 
may expose patients to increased risk of contracting the infection. Another reason is that subjects 
with HHT often suffer from medical conditions that may negatively influence the clinical course 
of COVID-19. These include chronic anemia, heart failure, pulmonary arteriovenous 
malformations (AVMs), and pulmonary hypertension [1]. All these diseases may be associated 
with chronic hypoxemia, which might further worsen in case of COVID-19 pneumonia. Particular 
attention should then be paid to the fact that subjects affected by COVID-19 seem to be at 
increased risk of thrombosis [2]. This is a delicate issue for HHT patients, because it has been 
demonstrated that, despite the presence of an overwhelming bleeding propensity, they may also 
suffer from thrombotic complications. Indeed, they may develop paradoxical thromboembolic 
stroke from pulmonary AVMs and also possess an inherent prothrombotic state related to 
disturbances in the regulation of coagulation at the endothelial surface, with levels of coagulation 
Factor VIII (FVIII) being higher in HHT subjects than the general population and the degree of 
FVIII elevation correlating with thrombotic risk [3]. It should also be considered that some HHT 
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for thrombosis or interfere with the natural clot disintegration, such as thalidomide, pomalidomide, 
tamoxifen, pazopanib, bevacizumab, aminocaproic acid, and tranexamic acid [4]. These people 
might therefore be at even higher risk of coagulopathy in case of SARS-CoV-2 infection. The 
other side of the coin is that antithrombotic therapy cannot be used lightly in HHT, because this 
disease primarily is a hemorrhagic disorder, characterized by the presence not only of epistaxis, 
but also of vascular malformations in the brain and gastrointestinal telangiectasia [1]. We have 
recently shown that antithrombotic therapy may be well tolerated by subjects with HHT, but this 
certainly requires a careful evaluation by experienced physicians [5]. Indeed, there are other 
studies that report significant worsening of epistaxis and increased gastrointestinal bleeding in 
HHT subjects treated with anticoagulants [6,7]. We are not fully satisfied with the suggestions that 
medical societies are giving on this issue. For instance, in the ISTH interim guidance on 
recognition and management of coagulopathy in COVID-19, that has been recently published in 
the Journal of Thrombosis and Haemostasis, the only contraindications that are mentioned, 
regarding the use of heparins in hospitalized COVID-19 patients, are active bleeding and reduced 
platelet count (less than 25x109/L) [8]. Not to mention the fact that many physicians around the 
world have the feeling that standard pharmacological thromboprophylaxis is not enough and 
advocate the use of higher, and even therapeutic, doses of heparin to prevent thrombotic 
complications in hospitalized COVID-19 patients [9]. The risk-benefit ratio of such therapeutic 
approach in HHT patients is completely unknown. Last but not least is the psychological impact 
that the COVID-19 pandemic may have on subjects affected by HHT. A high prevalence of 
depressive and post-traumatic stress disorder symptoms has been reported in HHT [10] and we 
know, based on our personal experience, that subjects with HHT require particular care also at the 
psychological level. Isolation, social distancing, hospital restrictions, and closure of many HHT 
outpatient clinics may have severe deleterious effects on the mood of these patients. We call for a 
sustained effort by the medical and scientific HHT community to reduce the burden of COVID-19 
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